OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
October 26, 2022
AstraZeneca’s Imjudo (tremelimumab) was approved by FDA in combination with Imfinzi (durvalumab) for treating unresectable liver cancer.
October 25, 2022
Under the new collaboration with Tempus, GSK will have access to de-identified patient data to accelerate drug discovery, improve clinical trial design, and speed up enrollment.
October 21, 2022
Aenova Group and Microcaps are partnering to enable new customized formulations for product development and life cycle management solutions.
October 18, 2022
In this episode, Ana Ladino provides expert insight into novel excipients in the current and future drug development landscape.
October 16, 2022
Patient centricity is driving change in drug discovery and development, leading to a a new dawn in therapeutics.
An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.
October 15, 2022
How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.
October 14, 2022
One company reaches beyond traditionally-conceived male contraceptives with Vasalgel, a reversible hydrogel injectable.
October 07, 2022
Emerging new technologies and disruptive manufacturing concepts are providing new opportunities for pharmaceutical companies.
October 06, 2022
Sponsors should explore key considerations ahead of choosing a new outsourcing partner.